




**Supplementary Figure 1** Muscle dystrophic phenotype is absent at P6 in PKO mice. (a) Size comparison of the P6 control and PKO mice. (b) H&E staining of hind-limb muscles from control and PKO mice at P6. (c) Immunohistochemical analysis of CD3 (green) and F4/80 (red) in control and PKO muscles at P6. Scale bars represent 25  $\mu\text{m}$  in **b** and 50  $\mu\text{m}$  in **c**.




**Supplementary Figure 2** Specificity of *Pdgfrβ*-driven *Cre* in injured conditions. Immunohistochemical analyses were performed on muscle sections from laminin-deficient reporter ( $F/F:Ai14:Pdgfr\beta-Cre^+$ ) mice. (a-f) TdT (red) expression co-localized with PDGFR $\beta$  (a, green), PW1 (d, green), but not Pax7 (b, green), PDGFR $\alpha$  (c, green), CD31 (e, green) or CD45 (f, green) in  $F/F:Ai14:Pdgfr\beta-Cre^+$  reporter mice. TdT, tdTomato. Scale bars represent 50  $\mu$ m.




**Supplementary Figure 3** Representative FACS plots and gating boundaries. **(a)** Representative FACS plot for  $PDGFR\beta^+CD31^-CD45^-$  population. The gating boundary was determined based on  $PDGFR\beta$ -FMO control. **(b)** Representative FACS plot and gating boundary for  $SM/C-2.6^+CD31^-CD45^-Sca1^-$  cells (satellite cells). **(c)** Representative FACS plot for  $PDGFR\alpha^+CD31^-CD45^-$  population (FAPs). The gating boundary was determined based on  $PDGFR\alpha$ -FMO control. **(d)** Representative FACS plot and gating boundary for  $CD34^+Sca1^{Med}CD45^-$  cells (PICs).



**Supplementary Figure 4** Characterization of FACS-isolated PDGFR $\beta$ <sup>+</sup> cells and satellite cells. **(a)** CD13 (green) and NG2 (red) expression in PDGFR $\beta$ <sup>+</sup> cells isolated from wild-type mice. **(b)** ALP (green) expression in PDGFR $\beta$ <sup>+</sup> cells isolated from wild-type mice. **(c and d)** PDGFR $\beta$  **(c, green)** and PDGFR $\alpha$  **(d, green)** expression in satellite cells isolated from wild-type mice. Scale bar represents 20  $\mu$ m.




**Supplementary Figure 5** The proliferation of PDGFR $\beta^+$  cells is unchanged in PKO mice at P6. (a) PDGFR $\beta$  (red) and Ki67 (green) expression in hind-limb muscles from P6 mice. (b, c) Quantification of PDGFR $\beta$  expression and PDGFR $\beta^+$ Ki67 $^+$  cells in a.  $n=3$ . Scale bar represents 100  $\mu$ m. Results are shown as mean  $\pm$  SD.




**Supplementary Figure 6** Loss of laminin in PDGFR $\beta$ <sup>+</sup> cells does not induce apoptosis. (**a**, **b**) Quantification of TUNEL<sup>+</sup> cells in hind-limb muscles from 2-month-old mice (**a**) and freshly isolated PDGFR $\beta$ <sup>+</sup> cells (**b**). DNase I-treated PDGFR $\beta$ <sup>+</sup> cells were used as the positive control.  $n=4$ . Results are shown as mean  $\pm$  SD.






**Supplementary Figure 7** The proliferation of PDGFRβ<sup>+</sup> cells is unaltered in barium chloride-induced injury. (a) Edu (green), PDGFRβ (red), and laminin (blue) expression 5 days after barium chloride injection in the presence of saline or laminin. (b-d) Quantification of PDGFRβ expression (b), total Edu<sup>+</sup> (c), and Edu<sup>+</sup>PDGFRβ<sup>+</sup> cells (d) in a. *n*=3. Scale bar represents 25 μm. Results are shown as mean ± SD.




**Supplementary Figure 8** The myogenesis of PDGFR $\beta^+$  cells is unaffected at P6 in PKO mice. **(a)** S-Myosin (green) expression in hind-limb muscles from P6 control and PKO mice. **(b)** Quantification of S-Myosin expression in **a**.  $n=3$ . **(c)** E-Myosin (red) expression in hind-limb muscles from P6 control and PKO mice. **(d)** Quantification of E-Myosin expression in **c**.  $n=3$ . Scale bars represent 100  $\mu\text{m}$ . Results are shown as mean  $\pm$  SD.








**Supplementary Figure 9** The adipogenesis of PDGFR $\beta^+$  cells is unaffected at P6 in PKO mice. **(a)** Perilipin (green) expression in hind-limb muscles from P6 control and PKO mice. **(b)** Quantification of perilipin expression in **a**.  $n=3$ . **(c)** Oil Red O staining of hind-limb muscles from P6 control and PKO mice. Scale bars represent 100  $\mu\text{m}$ . Results are shown as mean  $\pm$  SD.



**Supplementary Figure 10** CMA1 does not regulate the differentiation of PDGFR $\beta^+$  cells. **(a)** RT-PCR analysis of *CMA1* expression in PDGFR $\beta^+$  cells. *Actin* was used as a loading control.  $n=3$ . **(b)** Western blot analysis of *CMA1* expression in PDGFR $\beta^+$  cells. GAPDH was used as a loading control.  $n=4$ . **(c)** Western blot analysis of perilipin expression in wild-type PDGFR $\beta^+$  cells treated with rabbit IgG or CMA1 antibody and PKO PDGFR $\beta^+$  cells treated with BSA or CMA1. GAPDH was used as a loading control.  $n=4$ . **(d)** Western blot analysis of S-Myosin expression in wild-type PDGFR $\beta^+$  cells treated with rabbit IgG or CMA1 antibody and PKO PDGFR $\beta^+$  cells treated with BSA or CMA1. GAPDH was used as a loading control.  $n=4$ . Results are shown as mean  $\pm$  SD. \* $p < 0.05$  (Student's *t*-test).



**Supplementary Figure 11** Exogenous laminin increases gpihbp1 expression in laminin  $\alpha 2$ -deficient (dyW) mice. Western blot analysis of gpihbp1 expression in PDGFR $\beta$ <sup>+</sup> cells isolated from wild-type, dyW, or laminin-treated dyW mice. GAPDH was used as a loading control.  $n=3$ . Results are shown as mean  $\pm$  SD. \* $p < 0.05$ ; \*\* $p < 0.01$  (Student's  $t$ -test).



**Supplementary Figure 12** Full size images of the blots. (a) Full blots for Figure 2g. (b) Full blots for Figure 5c. (c) Full blots for Figure 6b. (d) Full blots for Figure 7d. (e) Full blots for Figure 7e. (f) Full blots for Figure 7f. (g) Full blots for Figure 7g. (h) Full blots for Figure 7h. (i) Full blots for Figure 7i. (j) Full blots for Figure 8f. (k) Full blots for Figure 8g. (l) Full blots for Supplementary Figure 9a. (m) Full blots for Supplementary Figure 10b. (n) Full blots for Supplementary Figure 10c. (o) Full blots for Supplementary Figure 10d. (p) Full blots for Supplementary Figure 11.